Management of bleeding disorders in children
(2012) In Haemophilia 18(Suppl. 2). p.15-23- Abstract
- Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development,... (More)
- Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development, including the aims of the SIPPET study which is already ongoing and involves boys <6 years, and the potential of immune tolerance therapy for eradicating the inhibitor and permitting a resumption of standard dosing schedules. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2563227
- author
- Berntorp, Erik LU ; Halimeh, S. ; Gringeri, A. ; Mathias, M. ; Escuriola, C. and Perez, R.
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Blood Coagulation Factor Inhibitors: immunology Factor VIII: administration & dosage Factor VIII: therapeutic use Hemophilia A: drug therapy Hemophilia A: immunology
- in
- Haemophilia
- volume
- 18
- issue
- Suppl. 2
- pages
- 15 - 23
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000303155600004
- scopus:84860305819
- ISSN
- 1351-8216
- DOI
- 10.1111/j.1365-2516.2012.02796.x
- language
- English
- LU publication?
- yes
- id
- 7655060b-91d8-446e-ac23-b242cb956847 (old id 2563227)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22530575?dopt=Abstract
- date added to LUP
- 2016-04-01 09:56:37
- date last changed
- 2022-07-14 01:59:01
@article{7655060b-91d8-446e-ac23-b242cb956847, abstract = {{Haemophilia, if not properly managed, can lead to chronic disease and lifelong disabilities. The challenges and issues in infants/young children are different from those in older children and adults although episodes of bleeding still predominate as the diagnostic trigger. Awareness of clinical manifestations and treatment complications are crucial in instituting appropriate management and implementing preventive strategies. Currently, inhibitor development is a challenging complication of paediatric haemophilia and prophylaxis is emerging as the optimal preventive care strategy. In this section we will review some important aspects of haemophilia in children including early prophylaxis, current evidence relating to inhibitor development, including the aims of the SIPPET study which is already ongoing and involves boys <6 years, and the potential of immune tolerance therapy for eradicating the inhibitor and permitting a resumption of standard dosing schedules.}}, author = {{Berntorp, Erik and Halimeh, S. and Gringeri, A. and Mathias, M. and Escuriola, C. and Perez, R.}}, issn = {{1351-8216}}, keywords = {{Blood Coagulation Factor Inhibitors: immunology Factor VIII: administration & dosage Factor VIII: therapeutic use Hemophilia A: drug therapy Hemophilia A: immunology}}, language = {{eng}}, number = {{Suppl. 2}}, pages = {{15--23}}, publisher = {{Wiley-Blackwell}}, series = {{Haemophilia}}, title = {{Management of bleeding disorders in children}}, url = {{http://dx.doi.org/10.1111/j.1365-2516.2012.02796.x}}, doi = {{10.1111/j.1365-2516.2012.02796.x}}, volume = {{18}}, year = {{2012}}, }